Puma's fresh shiner, what the biotech IPO surge tells us, and the trouble with cancer R&D
Endpoints assesses the big biopharma stories of the week, with a little added commentary on what they mean for the industry.
Puma gets another shiner as BioTwitter chews on another morsel of information
One thing you don’t want to see in the final few days leading up to an FDA panel review of your big drug is trouble on the regulatory team. This, after all, is where the rubber hits the road for regulatory as they steer the application toward a group of people at the FDA and their chosen advisers who will offer their expert opinions on what you’ve been hoping to sell for badly needed revenue.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.